ES2097748T3 - Uso de derivados funcionales de la molecula de adhesion intercelular icam-1 en la terapia antivirica. - Google Patents

Uso de derivados funcionales de la molecula de adhesion intercelular icam-1 en la terapia antivirica.

Info

Publication number
ES2097748T3
ES2097748T3 ES90104450T ES90104450T ES2097748T3 ES 2097748 T3 ES2097748 T3 ES 2097748T3 ES 90104450 T ES90104450 T ES 90104450T ES 90104450 T ES90104450 T ES 90104450T ES 2097748 T3 ES2097748 T3 ES 2097748T3
Authority
ES
Spain
Prior art keywords
icam
antiviric
molecula
therapy
functional derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90104450T
Other languages
English (en)
Inventor
Timothy Alan Springer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Disease Institute Inc
Original Assignee
Immune Disease Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Disease Institute Inc filed Critical Immune Disease Institute Inc
Application granted granted Critical
Publication of ES2097748T3 publication Critical patent/ES2097748T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Abstract

LA INVENCION CONCIERNE AL USO DE DERIVADOS FUNCIONALES DE ICAM-1 PARA TRATAR INFECCIONES VIRICAS. LA INVENCION TAMBIEN PROVEE UNA VACUNA PARA PREVENIR TALES INFECCIONES, Y UNA PRUEBA DE DIAGNOSTICO PARA DETERMINAR LA EXISTENCIA Y EXTENSION DE TALES INFECCIONES.
ES90104450T 1989-03-16 1990-03-08 Uso de derivados funcionales de la molecula de adhesion intercelular icam-1 en la terapia antivirica. Expired - Lifetime ES2097748T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32407389A 1989-03-16 1989-03-16
US45429289A 1989-12-22 1989-12-22

Publications (1)

Publication Number Publication Date
ES2097748T3 true ES2097748T3 (es) 1997-04-16

Family

ID=26984265

Family Applications (2)

Application Number Title Priority Date Filing Date
ES90104450T Expired - Lifetime ES2097748T3 (es) 1989-03-16 1990-03-08 Uso de derivados funcionales de la molecula de adhesion intercelular icam-1 en la terapia antivirica.
ES96107522T Expired - Lifetime ES2177695T3 (es) 1989-03-16 1990-03-08 Uso de derivados funcionales de la molecual de adhesion intercelular icam-1 en terapia antiviral.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES96107522T Expired - Lifetime ES2177695T3 (es) 1989-03-16 1990-03-08 Uso de derivados funcionales de la molecual de adhesion intercelular icam-1 en terapia antiviral.

Country Status (13)

Country Link
EP (2) EP0391088B1 (es)
JP (1) JP3166854B2 (es)
KR (1) KR0178024B1 (es)
AT (2) ATE219838T1 (es)
AU (1) AU648016B2 (es)
CA (1) CA2012125C (es)
DE (2) DE69029528T2 (es)
DK (2) DK0391088T3 (es)
ES (2) ES2097748T3 (es)
GR (1) GR3022846T3 (es)
HK (1) HK1003104A1 (es)
HU (1) HU220235B (es)
NZ (1) NZ232920A (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
EP0362531B1 (en) * 1988-09-01 1999-11-10 Bayer Corporation A human rhinovirus receptor protein that inhibits virus infectivity
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
CA2011633C (en) * 1989-03-09 2007-05-15 Timothy A. Springer Intercellular adhesion molecule - 2 and its binding ligands
WO1991018010A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of viral infection using intercellular adhesion molecule-1-like peptides and/or analogues thereof
ES2134762T3 (es) * 1990-07-20 1999-10-16 Bayer Ag Formas multimericas de proteinas receptoras de rinovirus humanos.
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5871733A (en) * 1990-07-20 1999-02-16 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
EP0510483A1 (en) * 1991-04-22 1992-10-28 Boehringer Ingelheim Pharmaceuticals Inc. Method for the detection of viruses
WO1994000143A1 (en) * 1992-06-01 1994-01-06 New England Medical Center Hospitals, Inc. Blocking intercellular interactions with cd43 chimeric molecules
DE4335273A1 (de) * 1993-10-15 1995-04-20 Univ Ludwigs Albert Peptide zur Tumortherapie
EP0757697A4 (en) * 1994-04-12 2000-05-17 Boehringer Ingelheim Pharma USE OF AGENTS INHIBITING INTERCELLULAR INTERACTION IN THE TREATMENT OF VIRAL BREATH INFECTION
EP0762886A4 (en) * 1994-04-19 1999-03-31 Univ Kansas ICAM-1 / LFA-1 SHORT CHAIN PEPTIDES AND METHODS FOR USE THEREOF
DE69631381T2 (de) * 1995-11-22 2004-10-21 Univ Montana State Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
CA2244894A1 (en) * 1996-03-06 1997-09-12 Boehringer Ingelheim Pharmaceuticals, Inc. Intercellular adhesion molecule powder formulation
US6075004A (en) 1996-04-26 2000-06-13 The University Of Kansas Peptide compositions which induce immune tolerance and methods of use
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
DE60042069D1 (de) 1999-06-24 2009-06-04 Univ Johns Hopkins Zusammensetzungen und methoden zur vorbeugung transepithelialer übertragung von hiv
GB0216729D0 (en) * 2002-07-18 2002-08-28 Glaxo Group Ltd Animal models

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2080044T3 (es) * 1987-05-04 1996-02-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular y sus ligandos de fijacion.
CA1341055C (en) * 1987-12-08 2000-07-18 Alan Mcclelland Transfectant cell lines which express the major human rhinovirus receptor
EP0362531B1 (en) * 1988-09-01 1999-11-10 Bayer Corporation A human rhinovirus receptor protein that inhibits virus infectivity
WO1990003400A1 (en) * 1988-09-28 1990-04-05 Dana-Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
NO900155L (no) * 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.

Also Published As

Publication number Publication date
DE69029528T2 (de) 1997-06-26
ATE219838T1 (de) 2002-07-15
HU220235B (hu) 2001-11-28
DE69029528D1 (de) 1997-02-13
EP0745852B1 (en) 2002-06-26
HUT56133A (en) 1991-07-29
DK0391088T3 (da) 1997-06-16
DE69033983D1 (de) 2002-08-01
CA2012125A1 (en) 1990-09-16
NZ232920A (en) 1997-05-26
ATE146968T1 (de) 1997-01-15
JP3166854B2 (ja) 2001-05-14
KR900013984A (ko) 1990-10-22
EP0391088B1 (en) 1997-01-02
HU901585D0 (en) 1990-06-28
AU648016B2 (en) 1994-04-14
ES2177695T3 (es) 2002-12-16
DE69033983T2 (de) 2003-03-20
HK1003104A1 (en) 1998-10-09
GR3022846T3 (en) 1997-06-30
KR0178024B1 (ko) 1999-03-20
JPH0372430A (ja) 1991-03-27
EP0745852A1 (en) 1996-12-04
EP0391088A3 (en) 1991-10-02
EP0391088A2 (en) 1990-10-10
DK0745852T3 (da) 2002-10-14
CA2012125C (en) 2003-07-29
AU5129490A (en) 1990-09-20

Similar Documents

Publication Publication Date Title
ES2097748T3 (es) Uso de derivados funcionales de la molecula de adhesion intercelular icam-1 en la terapia antivirica.
EA199800946A1 (ru) Концентрированный препарат антител
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
EA199900553A1 (ru) Чрескожная терапевтическая система
DK1036058T3 (da) Adamantanderivater
DK1036059T3 (da) Adamantanderivater
BR9506882A (pt) Indutor de paraimunidade com base em componentes de poxvírus processo de preparação do mesmo uso dos indutores de paraimunidade e cepas de poxvírus
FI944600A0 (fi) Imidatsol-4-yylipiperidiinijohdannaisia, niiden valmistus ja niiden käyttö terapiassa
IT1094434B (it) Cinnamoil piperazione e cinnamoil omopiperazione,procedimento per la loro preparazione e loro applicazione in terapia
NL970030I2 (nl) N-(aminoalkylfenyl)sulfonamiden, de bereiding daarvan en de therapeutische toepassing daarvan.
ES2063202T3 (es) Nuevas 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y -tionas y su uso en la prevencion o tratamiento del sida.
ITMI912509A1 (it) Uso della nimesulide nel trattamento della cataratta
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
DK170987A (da) N-substituerede benzamider, deres fremstilling og anvendelse
EE9900135A (et) N-(2-bensotiasolüül)-1-piperidiinetaanamiini derivaadid, nende valmistamine ja kasutamine raviks
DK131586A (da) Transdermalt, antiallergisk, farmaceutisk praeparat
PT1007052E (pt) Combinacoes de progestinas de crescimento do endometrico e progestinas de atropia do endometrio com estrogenios, em contracepcao oral
IT8920357A0 (it) Nuovi derivati della serina, loro processo di preparazione e impiego in terapia umana.
ES2010963A4 (es) Derivados de n - cicloalkilaminoetilbenzamida, su sintesis y preparacion farmaceutica
NO922437D0 (no) Terapeutisk aktive fluorsubstituerte benzimidazoler, fremgangsmaate for deres fremstilling samt deres anvendelse
IT8619457A0 (it) Derivati insaturi cicloalifatici, loro procedimenti di prepatazione e loro impiego in terapia e in cosmetica.
PT958290E (pt) Derivados de 1,4-di-hidropiridina e seu uso em terapia
IT8121838A0 (it) N-aril-2-ossazolidinoni, loro procedimento di preparazione e loro applicazione in terapia
IT1219568B (it) Uso di enalapril nel trattamento terapeutico delle cefalee essenziali
IT8919801A0 (it) Gel di antracicline e loro uso terapeutico.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 391088

Country of ref document: ES